Emcure Pharmaceuticals declares ₹3.60 per share final dividend for FY26
- Emcure Pharmaceuticals declares a final dividend of ₹3.60 per equity share for FY26
- Shareholders approved the reappointment of Satish Mehta as Managing Director & CEO
- Chairman Berjis Desai retired from the board during the 45th AGM held on September 21, 2026
- The meeting was conducted via video conferencing with no qualifications in audit reports
*this image is generated using AI for illustrative purposes only.
Emcure Pharmaceuticals declared a final dividend of ₹3.60 per equity share for FY26 during its 45th Annual General Meeting held on September 21, 2026. The payout applies to shares with a face value of ₹10 each.
The meeting, conducted via video conferencing, also addressed key board changes. Members approved the reappointment of Mr. Satish Mehta as Managing Director and Chief Executive Officer. Additionally, the company noted the retirement of Mr. Berjis Desai, who served as Chairman and Non-Executive Non-Independent Director.
Board and Governance Updates
The AGM transacted several ordinary and special resolutions regarding director appointments and auditor remuneration:
- Reappointment of Mrs. Namita Thapar as a Director retiring by rotation
- Reappointment of Dr. Mukund Gurjar as Whole-time Director
- Appointment of Mr. Raghu Kumar as an Independent Director
- Ratification of remuneration payable to the Cost Auditor for FY27
Mr. Berjis Desai chaired the proceedings before stepping down, expressing gratitude to stakeholders. Ms. Amruta Yangalwar, Company Secretary and Compliance Officer, managed the meeting logistics and e-voting process.
What the Numbers Show
The declaration of a ₹3.60 dividend reflects the company’s capital return policy for FY26. The absence of qualified remarks in the Statutory Auditor’s Report and Secretarial Audit Report indicates clean compliance for the fiscal year ended March 31, 2026.
Historical Stock Returns for Emcure Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.27% | +1.54% | +7.19% | +31.20% | +49.85% | +47.84% |
How might the reappointment of Satish Mehta as MD and CEO influence Emcure's strategic focus on R&D and international expansion in the coming fiscal years?
What impact is the appointment of Raghu Kumar as an Independent Director expected to have on the company's corporate governance and board decision-making processes?
Given the clean audit reports, how does Emcure plan to leverage its strong compliance standing to attract institutional investors or pursue potential M&A activities?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
